Liver

Genome BC Invests $1M in Breakthrough Solution for Detecting Chronic Liver Disease, Closing Off Sonic Incytes’ $3.5M Financing Round

Thursday, May 28, 2020 - 4:00pm

Vancouver based Sonic Incytes is developing a breakthrough, point of care ultrasound solution for assessing and managing chronic liver disease an emerging global health crisis, affecting one in four persons worldwide.

Key Points: 
  • Vancouver based Sonic Incytes is developing a breakthrough, point of care ultrasound solution for assessing and managing chronic liver disease an emerging global health crisis, affecting one in four persons worldwide.
  • Fatty liver disease is the fastest growing and largest segment of chronic liver disease, driven largely by the increasing prevalence of diabetes and obesity.
  • Sonic Incytes portable, handheld solution uses technology similar to MRI elastography, quantifying liver disease using 3D tissue sampling.
  • www.genomebc.ca
    About Sonic Incytes Medical Corp.:
    Recognizing the rise of fatty liver disease, Sonic Incytes has a mission to reduce the disease by enabling routine assessment and management of liver health.

TransMedics Announces Positive Top-line Results from U.S. Pivotal OCS™ Liver PROTECT Trial

Tuesday, May 26, 2020 - 12:09pm

ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported positive top-line results from its U.S. Pivotal OCS Liver PROTECT Trial.

Key Points: 
  • ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported positive top-line results from its U.S. Pivotal OCS Liver PROTECT Trial.
  • In the OCS Liver PROTECT Trial, 155 donor livers, including both DBD and DCD, were instrumented on the OCS Liver, of which 152 were successfully transplanted, yielding a 98.1% utilization rate.
  • Results from the OCS Liver PROTECT Trial set the stage for transformative changes in the field of liver transplantation by validating the benefits of reducing ischemic injury on the donor liver while continuously optimizing perfusion and assessing liver function on the OCS System, said Dr. James Markmann, MD PhD, Chief Division of Transplant Surgery at Massachusetts General Hospital and the lead investigator of the OCS Liver PROTECT Trial.
  • About OCS Liver PROTECT Trial:
    The OCSLiver PROTECT Trial is a two-armed, multicenter, prospective, randomized, controlled pivotal trial to evaluate the effectiveness and safety of the OCS Liver to preserve and assess donor livers intended fortransplantation.

Albireo to Present at 2020 Jefferies Virtual Healthcare Conference

Tuesday, May 26, 2020 - 1:00pm

BOSTON, May 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.(Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies Virtual Healthcare Conference on Tuesday, June 2, at 8:30 a.m. EDT.

Key Points: 
  • BOSTON, May 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.(Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies Virtual Healthcare Conference on Tuesday, June 2, at 8:30 a.m. EDT.
  • The live webcast of the presentation will be accessible from the Media & Investors page of Albireos website, ir.albireopharma.com .
  • To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.
  • Albireo was spun out fromAstraZenecain 2008.Albireo Pharmais located inBoston, Mass., and its key operating subsidiary is located inGothenburg, Sweden.

The Europe millets market was valued at US$ 1,327.96 million in 2018 and is expected to grow at a CAGR of 5.4% from 2019 to2027 to reach US$ 2,132.00 million by 2027

Saturday, May 23, 2020 - 2:05am

The Europe millets market was valued at US$ 1,327.96 million in 2018 and is expected to grow at a CAGR of 5.4% from 2019 to2027 to reach US$ 2,132.00 million by 2027.

Key Points: 
  • The Europe millets market was valued at US$ 1,327.96 million in 2018 and is expected to grow at a CAGR of 5.4% from 2019 to2027 to reach US$ 2,132.00 million by 2027.
  • Millets are an ideal food for people suffering from chronic diseases such as diabetes and heart diseases.
  • Regular consumption of millets helps in preventing gastrointestinal problems and other diseases related to kidney and liver.
  • Some of the players present in the Europe millets market are Just Organik, Shimla Hills Offerings Pvt.Ltd, Sresta Natural Bioproducts Pvt.

Battle Fatty Liver Disease and Obesity, Inform Cost-Effective Treatment Decisions: Echosens Articulates Value of Non-Invasive Diagnostic Tool, FibroScan

Wednesday, May 20, 2020 - 3:44pm

Echosens , a high-technology company offering the FibroScan family of products, today announces the release of its white paper, Two-Fold Epidemic: Fatty Liver Disease and Obesity Demand Proactive Steps, Earlier Identification of Liver Damage .

Key Points: 
  • Echosens , a high-technology company offering the FibroScan family of products, today announces the release of its white paper, Two-Fold Epidemic: Fatty Liver Disease and Obesity Demand Proactive Steps, Earlier Identification of Liver Damage .
  • The added assessment of liver health enables heath care professionals to make more informed treatment decisions about liver health and may reduce the need for expensive and more invasive testing.
  • The alarming rise in adult obesity rates and related fatty liver disease in the United States and worldwide has led to the need for increased scrutiny of liver damage and associated health issues, says Jon Gingrich, CEO, Echosens North America.
  • Non-alcoholic fatty liver disease (NAFLD) affects roughly 100 million Americans and costs the U.S. healthcare system $32 billion annually.

Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis

Monday, May 18, 2020 - 12:00pm

In the Phase II study, 25 mg of Namodenoson was shown to reduce hepatic fibrosis (scar tissue in the liver resulting from the liver trying to repair itself), reduce steatosis (fat buildup in the liver), and improve the FAST score, a measure for NASH (liver stiffness and an enzymatic biomarker of liver damage).

Key Points: 
  • In the Phase II study, 25 mg of Namodenoson was shown to reduce hepatic fibrosis (scar tissue in the liver resulting from the liver trying to repair itself), reduce steatosis (fat buildup in the liver), and improve the FAST score, a measure for NASH (liver stiffness and an enzymatic biomarker of liver damage).
  • Patients treated with 25 mg of Namodenoson had a statistically significant reduction in hepatic fibrosis as measured by the Fibrosis-4 (FIB-4) score, as compared to placebo.
  • The data show that Namodenoson reversed and eliminated NASH, and may prevent the progression of NAFLD into NASH.
  • Patients with evidence of an active inflammation were treated twice daily with 12.5 mg (n=21) or 25 mg (n=19) of oral Namodenoson vs. placebo (n=20).

Organ Transplant Industry Analysis 2015-2025 by Type, Sex, Product, Organ, Types of Transplant, Company and Region - Includes COVID-19 Implications

Friday, May 15, 2020 - 3:45pm

The Global Organ Transplant Market is expected to grow at a robust CAGR during the forecast period.

Key Points: 
  • The Global Organ Transplant Market is expected to grow at a robust CAGR during the forecast period.
  • The market for organ transplant is driven by the growing old-age segment cross the world along with increasing cases of organ failures.
  • Additionally, alcohol consumption has increased over the years, which usually damages the liver; thereby, positively impacting the organ transplant market.
  • The Global Organ Transplant Market is segmented on the basis of type, sex, product, organ, types of transplant and region.

Amsety's New Amsety Initiative to Provide Liver-Healthy Nutrition to Healthcare Workers at the Frontline

Wednesday, May 13, 2020 - 1:38pm

CARLSBAD, Calif., May 13, 2020 /PRNewswire/ --Amsety donates 50 Frontline Liver Support Boxes to medical facilities as part of the Frontline Liver Support Initiative.

Key Points: 
  • CARLSBAD, Calif., May 13, 2020 /PRNewswire/ --Amsety donates 50 Frontline Liver Support Boxes to medical facilities as part of the Frontline Liver Support Initiative.
  • Furthermore, 97% of liver health experts view nutrition as important for liver health ahead of any other factor.
  • To honor and support our healthcare workers, Amsety donates the Frontline Liver Support Boxes of Amsety Nutrition Bars.
  • To raise awareness on liver health in the U.S., Amsety published educational eBooks on liver health such as the "Super 16 Diet for Liver Health", "The Liver-Healthy Cookbook", and "A Guide to Liver Health".

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monday, May 11, 2020 - 10:01pm

The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The Compensation Committee of Mirums Board of Directors approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The awards are subject to the terms and conditions of Mirums 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • The companys lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Galmed Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on Thursday May 14

Thursday, May 7, 2020 - 1:30pm

The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells.

Key Points: 
  • The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells.
  • Aramchol has been granted Fast Track designation status by the FDA for the treatment of NASH.
  • NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.
  • Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases.